Systemic Therapies for mHSPC and Castrate Resistant Prostate Cancer

Systemic Therapies for Metastatic Hormone Sensitive Prostate Cancer and Castrate Resistant Prostate Cancer Host: Jay D. Raman, MD, FACS Co-Host: Alicia Morgans, MD, MPH and Kelly Stratton, MD CME Available: auau.auanet.org/node/37317 At the conclusion of this activity, participants will be able to: 1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients. 2. Prioritize or stratify treatment options for metastatic prostate cancer. 3. Describe the mechanism of action and role of immune checkpoint inhibitors for advanced prostate cancer. 4. Identify management of side effects and adverse events that patients experience for systemic therapies for advanced prostate cancer. ACKNOWLEDGEMENTS: This series is supported by independent educational grants from: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc. Sanofi Genzyme